GBS Venture Partners

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Euthymics Bioscience, Inc., a neuroscience-focused-clinical-stage biopharmaceutical company, that develops therapeutics, which help patients with withdrawal symptoms, impulsivity, and cravings. It develops a medicine for alcohol use disorder and smoking cessation. Euthymics Bioscience, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.

Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.

OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.

AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.

Aidmedics is a medical devices company that develops a device that identifies night-time hypoglycaemia to alert patients & care takers. It offers The HypoMon, an alarm system that identifies night-time hypos in children and young adults aged between 10 and 25 years with type 1 diabetes. It serves care takers, clients, and health professionals in the United States, Europe, Australia, and New Zealand. AIMEDICS Pty Ltd was founded in 2001 and is based in Eveleigh, Australia with an additional office in Warwick, United Kingdom.

Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.

Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

Viveve is a women's sexual health company that develops non-surgical treatment for women's sexual health. It focuses on developing a Viveve procedure, a non-surgical treatment for women who have experienced vaginal looseness and loss of physical sensation that is common to women after vaginal childbirth. The company’s Viveve System is a radiofrequency device that uses low levels of energy to restore collagen fibers overstretched and damaged during vaginal childbirth. Viveve, Inc. was formerly known as TiVaMed, Inc. and changed its name to Viveve, Inc. in November 2009. The company was founded in 2005 and is based in Palo Alto, California.

Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.

At NovaSys Health they value your participation as a contracted provider. Roughly 11,000 providers in this region and over 4,300 providers in Arkansas have contracted with NovaSys Health making it one of the largest health plans in Arkansas. They take pride in the relationships that they have cultivated with providers.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..

ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of oncology drugs. The company's product candidates include omacetaxine mepesuccinate, an investigational small molecule agent that is in Phase 2/3 clinical trial for the treatment of chronic myelogenous leukemia, and is also in Phase 2 clinical trials for the treatment of acute myelogenous leukemia and myelodysplastic syndrome; and Quinamed, which is in Phase 2 clinical trial for the treatment of hormone refractory prostate cancer. It was formerly known as AGT Biosciences Limited and changed its name to ChemGenex Pharmaceuticals Ltd in June 2004. The company was founded in 1958 and is headquartered in Geelong, Australia.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Hatchtech is an Australian company developing a locally developed proprietary technology platform that will enable the creation of a new generation of lowtoxicity pest control products. Specifically, the patented technology allows the complete blocking of pest species egg hatch through a novel mode of action. The technology has applicability for controlling ectoparasites and other egg laying pests of humans, animal, crops and the built environment.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.

Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.

Euthymics Bioscience, Inc., a neuroscience-focused-clinical-stage biopharmaceutical company, that develops therapeutics, which help patients with withdrawal symptoms, impulsivity, and cravings. It develops a medicine for alcohol use disorder and smoking cessation. Euthymics Bioscience, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

NeuroVista Corporation, a medical device company, develops medical technologies for the management and treatment of epilepsy in the United States. It offers advisory technologies to help mitigate the uncertainty of when epileptic seizures may strike. The company was formerly known as BioNeuronics Corporation and changed its name to NeuroVista Corporation in May 2007. NeuroVista Corporation was incorporated in 2002 and is based in Seattle, Washington.

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Elastagen Pty Ltd., a clinical stage medical company, produces and sells products based on the human protein tropoelastin. The company offers injectable dermoaesthetic products, stretch mark products, scar revision and wound healing products, and sealant and osteoskeletal products for applications areas, including skin rejuvenation, scar remodeling, and tissue repair. It sells its products through online orders. Elastagen Pty Ltd. was founded in 2003 and is based in Eveleigh, Australia with production operations in Europe; and clinical operations in the United Kingdom. As of April 6, 2018, Elastagen Pty Ltd. operates as a subsidiary of Allergan plc.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

Founded in 2004, Applied Physiology develops and commercializes treatment guidance systems intended to transform the care of critically-ill patients. The company's main focus is on real-time circulation management with its Navigator™ product. Applied Physiology has offices in Australia and the United Kingdom.

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.

CHF Solutions, Inc., a medical device company, focuses on developing, manufacturing, and commercializing devices used in ultrafiltration therapy. The company’s commercial product is the Aquadex FlexFlow System, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct Salesforce in the United States; and through independent specialty distributors primarily in the United Kingdom, Italy, Spain, Germany, Austria, Switzerland, Southeast Asia, Brazil, India, and Greece. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Moximed, Inc. develops a joint preserving option for patients with knee osteoarthritis. The company offers Atlas System, an implantable joint unloader that works like a shock absorber for a patient with medial compartment knee osteoarthritis, or suffering from pain on the medial (inner) side of the knee, or desire to maintain high activity or productivity levels. It serves patients and medical professionals worldwide. Moximed, Inc. was formerly known as ExploraMed NC4, Inc. The company was incorporated in 2006 and is based in Hayward, California.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.